Collectively, these findings indicate that ZAP expression levels are negatively correlated with the replication and oncolytic effects of M1, suggesting that ZAP may be useful as a biomarker with which the sensitivity of bladder cancers to M1 therapy can be assessed in affected patients. The gene discussed is ZC3HAV1; the disease is urinary bladder cancer.